Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5367-5374

  Nielsen, Torsten O ^a   Hsu, Forrest D ^a   Jensen, Kristin ^b   Cheang, Maggie ^a   Karaca, Gamze ^d,e   Hu, Zhiyuan ^d,e   Hernandez Boussard, Tina ^c   Livasy, Chad ^d,e   Cowan, Dave ^d,e   Dressler, Lynn ^d,e   Akslen, Lars A ^f   Ragaz, Joseph ^g   Gown, Allen M ^h   Gilks, C Blake ^a   Van De Rijn, Matt ^b   Perou, Charles M ^d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g ROYAL VICTORIA HOSPITAL   (Canada)

^h PHENOPATH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; STEM CELL FACTOR;

ADOLESCENT; ADULT; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DNA MICROARRAY; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEOPLASM INVASIVENESS; NEOPLASMS, BASAL CELL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 4143150688     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0220     Document Type: Article

References (28)

1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
2. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
3. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature (Lond.) 2002;415:530-6.
4. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
5. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
6. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Investig 2002;82:1525-33.
7. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (Bethesda) 2003;95:1482-5.
8. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004;64: 4218-26.
9. Sherlock G, Hernandez-Boussard T, Kasarskis A, et al. The Stanford microarray database. Nucleic Acids Res 2001;29:152-5.
10. Ragaz J, Olivotto IA, O'Reilly S, et al. The significance of mastectomy in patients with locally advanced breast cancer treated with preoperative (neoadjuvant) therapy: is there a need for randomization? Proc Am Soc Clin Oncol 1991;10:41a.
11. Ragaz J, Baird R, Rebbeck P, Goldie J, Coldman A, Spinelli J. Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer (Phila.) 1985;56:719-24.
12. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-62.
13. Ragaz J, Coldman AJ, Le N, Olivotto I, Fang R, Hislop TG. Incidence of second cancers in patients with primary breast cancer: analysis of BC Cancer Registry cohorts with differing policies of adjuvant therapy between 1970-1994. Proc Am Soc Clin Oncol 1998;17: 421a.
14. Nielsen TO, Andrews HN, Cheang M, et al. Expression of the insulin-like growth factor-1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004;64: 286-91.
15. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.
16. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
17. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-65.
18. Breslow NE. A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 1970;57: 579-94.
19. Nielsen TO, Hsu FD, O'Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 2003;163:1449-56.
20. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature (Lond.) 2000;406:747-52.
21. Boecker W, Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif 2003;36 (Suppl 1):73-84.
22. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10:178-83.
23. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-29.
24. Bocker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 1992;421:315-22.
25. Wetzels RH, Kuijpers HJ, Lane EB, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991;138:751-63.
26. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet 2002;32 (Suppl):533-40.
27. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002;20:2217-9.
28. Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors. Oncology 2002;63 (Suppl 1):6-16.